FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1796184815> ?p ?o ?g. }

• W1796184815 endingPage "141" @default.
• W1796184815 startingPage "135" @default.
• W1796184815 abstract "PURPOSE Megestrol acetate has been reported to improve appetite and quality of life and to decrease nausea and vomiting in patients with cancer anorexia/cachexia. The present trial was formulated to evaluate the impact of megestrol acetate on quality of life, toxicity, response, and survival in individuals with extensive-stage small-cell lung cancer who received concomitant chemotherapy. PATIENTS AND METHODS Patients were randomized to receive megestrol acetate 800 mg/d orally or placebo. In addition, all patients were scheduled to receive a maximum of four cycles of cisplatin and etoposide chemotherapy. Quality of life was self-assessed at entry onto study, with every cycle of chemotherapy, and 4 months thereafter with a linear visual analog scale. Toxicity was evaluated by patient questionnaire and investigator reports. RESULTS A total of 243 eligible patients were randomized. Those who received megestrol acetate had increased nonfluid weight gain (P = .004) and significantly less nausea (P = .0002) and vomiting (P = .02). Significant thromboembolic phenomena occurred more often in patients who received megestrol acetate versus placebo (9% v 2%, P = .01). Patients who received megestrol acetate had more edema (30% v 20%, P = .002), an inferior response rate to chemotherapy (68% v 80%, P = .03), and a trend for inferior survival duration (median, 8.2 v 10.0 months, P = .49). These findings may have been influenced by a poorer quality of life of the megestrol acetate group at study initiation. There were no significant changes in quality of life scores over time between either of the study arms. CONCLUSION Megestrol acetate cannot be routinely recommended for all patients with small-cell lung cancer at the time of chemotherapy initiation. Rather, its therapeutic ratio may be more favorable for patients with problematic cancer anorexia/cachexia." @default.
• W1796184815 created "2016-06-24" @default.
• W1796184815 creator A5002406337 @default.
• W1796184815 creator A5002408510 @default.
• W1796184815 creator A5004068548 @default.
• W1796184815 creator A5023554560 @default.
• W1796184815 creator A5027623921 @default.
• W1796184815 creator A5031000802 @default.
• W1796184815 creator A5039867739 @default.
• W1796184815 creator A5040261194 @default.
• W1796184815 creator A5049001174 @default.
• W1796184815 creator A5051200321 @default.
• W1796184815 creator A5058147268 @default.
• W1796184815 creator A5064726197 @default.
• W1796184815 creator A5080719115 @default.
• W1796184815 creator A5082829293 @default.
• W1796184815 creator A5090620014 @default.
• W1796184815 date "1996-01-01" @default.
• W1796184815 modified "2023-10-13" @default.
• W1796184815 title "Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study." @default.
• W1796184815 cites W1794914953 @default.
• W1796184815 cites W1877611139 @default.
• W1796184815 cites W1881225095 @default.
• W1796184815 cites W1884032213 @default.
• W1796184815 cites W1884665868 @default.
• W1796184815 cites W1929485622 @default.
• W1796184815 cites W1962075013 @default.
• W1796184815 cites W1977057354 @default.
• W1796184815 cites W1983235754 @default.
• W1796184815 cites W2016414703 @default.
• W1796184815 cites W2020057881 @default.
• W1796184815 cites W2028332009 @default.
• W1796184815 cites W2039875234 @default.
• W1796184815 cites W2043759449 @default.
• W1796184815 cites W2069223603 @default.
• W1796184815 cites W2080633114 @default.
• W1796184815 cites W2085813303 @default.
• W1796184815 cites W2108207437 @default.
• W1796184815 cites W2123767004 @default.
• W1796184815 cites W2134488331 @default.
• W1796184815 cites W2148525389 @default.
• W1796184815 cites W2149860264 @default.
• W1796184815 cites W2177302713 @default.
• W1796184815 doi "https://doi.org/10.1200/jco.1996.14.1.135" @default.
• W1796184815 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8558188" @default.
• W1796184815 hasPublicationYear "1996" @default.
• W1796184815 type Work @default.
• W1796184815 sameAs 1796184815 @default.
• W1796184815 citedByCount "130" @default.
• W1796184815 countsByYear W17961848152012 @default.
• W1796184815 countsByYear W17961848152013 @default.
• W1796184815 countsByYear W17961848152014 @default.
• W1796184815 countsByYear W17961848152015 @default.
• W1796184815 countsByYear W17961848152017 @default.
• W1796184815 countsByYear W17961848152018 @default.
• W1796184815 countsByYear W17961848152020 @default.
• W1796184815 countsByYear W17961848152021 @default.
• W1796184815 countsByYear W17961848152022 @default.
• W1796184815 countsByYear W17961848152023 @default.
• W1796184815 crossrefType "journal-article" @default.
• W1796184815 hasAuthorship W1796184815A5002406337 @default.
• W1796184815 hasAuthorship W1796184815A5002408510 @default.
• W1796184815 hasAuthorship W1796184815A5004068548 @default.
• W1796184815 hasAuthorship W1796184815A5023554560 @default.
• W1796184815 hasAuthorship W1796184815A5027623921 @default.
• W1796184815 hasAuthorship W1796184815A5031000802 @default.
• W1796184815 hasAuthorship W1796184815A5039867739 @default.
• W1796184815 hasAuthorship W1796184815A5040261194 @default.
• W1796184815 hasAuthorship W1796184815A5049001174 @default.
• W1796184815 hasAuthorship W1796184815A5051200321 @default.
• W1796184815 hasAuthorship W1796184815A5058147268 @default.
• W1796184815 hasAuthorship W1796184815A5064726197 @default.
• W1796184815 hasAuthorship W1796184815A5080719115 @default.
• W1796184815 hasAuthorship W1796184815A5082829293 @default.
• W1796184815 hasAuthorship W1796184815A5090620014 @default.
• W1796184815 hasConcept C121608353 @default.
• W1796184815 hasConcept C126322002 @default.
• W1796184815 hasConcept C141071460 @default.
• W1796184815 hasConcept C142724271 @default.
• W1796184815 hasConcept C168563851 @default.
• W1796184815 hasConcept C204787440 @default.
• W1796184815 hasConcept C27081682 @default.
• W1796184815 hasConcept C2776694085 @default.
• W1796184815 hasConcept C2778119113 @default.
• W1796184815 hasConcept C2779320873 @default.
• W1796184815 hasConcept C2780580376 @default.
• W1796184815 hasConcept C2780723184 @default.
• W1796184815 hasConcept C2780852908 @default.
• W1796184815 hasConcept C42219234 @default.
• W1796184815 hasConcept C71924100 @default.
• W1796184815 hasConcept C90924648 @default.
• W1796184815 hasConceptScore W1796184815C121608353 @default.
• W1796184815 hasConceptScore W1796184815C126322002 @default.
• W1796184815 hasConceptScore W1796184815C141071460 @default.
• W1796184815 hasConceptScore W1796184815C142724271 @default.
• W1796184815 hasConceptScore W1796184815C168563851 @default.
• W1796184815 hasConceptScore W1796184815C204787440 @default.
• W1796184815 hasConceptScore W1796184815C27081682 @default.

• next